RxDoctor Payments Data

Carrie Lee, MD

Hematology & Oncology · Chapel Hill, NCNPI 1538281928

Payments from drug & device makers

$276,289in general payments, 2019–2025

Across 48 payments — averaging $5756.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$152K
  • Roche Products Limited$68K
  • EMD Serono, Inc.$37K
  • Incyte Corporation$13K
  • F. Hoffmann-la Roche AG$2K
  • Genentech, Inc.$2K
  • plus $2K from 4 others

What the payments were for

  • Speaking & faculty fees$2,42597%
  • Food & beverage$462%
  • Education$281%

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$276,289 in reported general payments places this provider in the 80th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$22,292
Medicare patients
58
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate44$709,360
TabrectaCapmatinib Hydrochloride13$300,033
LorbrenaLorlatinib11$148,165
LumakrasSotorasib13$137,445
EliquisApixaban56$39,713
Olanzapine25$365
Prochlorperazine Maleate26$304
Dexamethasone21$270
Ondansetron Hcl32$255
Oxycodone Hcl15$187
Prednisone15$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLorbrena, Eliquis$28$187,87767 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →